<i>Journal of Hepatology</i>｜Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway

doi:10.12449/JCH2502.gwqkjpwzjj2

Volume 41 Issue 2

Feb. 2025

Turn off MathJax

Article Contents

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(2): 364-364

PDF( 900 KB)

Journal of Hepatology｜Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway

DOI: 10.12449/JCH2502.gwqkjpwzjj2

Published Date: 2025-02-25

Abstract

FullText(HTML)

References(0)

References

Relative Articles

[1]	Journal of Hepatology｜TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway[J]. Journal of Clinical Hepatology, 2025, 41(3): 587-587. doi: 10.12449/JCH2503.gwqkjpwzjj5
[2]	Journal of Hepatology｜GRINA alleviates hepatic ischemia-reperfusion injury-induced apoptosis and ER-phagy by enhancing HRD1-mediated ATF6 ubiquitination[J]. Journal of Clinical Hepatology, 2025, 41(2): 382-382. doi: 10.12449/JCH2502.gwqkjpwzjj3
[3]	Liver International｜MASLD, At-Risk MASH and increased liver stiffness are associated with young adulthood obesity without residual risk after losing obesity[J]. Journal of Clinical Hepatology, 2025, 41(2): 400-400. doi: 10.12449/JCH2502.gwqkjpwzjj4
[4]	Hepatology International｜Non-canonical Wnt signaling pathway activated NFATC3 promotes GDF15 expression in MASH: prospective analyses of UK biobank proteomic data[J]. Journal of Clinical Hepatology, 2025, 41(3): 541-541. doi: 10.12449/JCH2503.gwqkjpwzjj2
[5]	Hepatology｜Health-Related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebocontrolled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis[J]. Journal of Clinical Hepatology, 2024, 40(10): 2120-2120. doi: 10.12449/JCH2410.gwqkjpwzjj2
[6]	Journal of Hepatology｜Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1777-1777. doi: 10.12449/JCH2409.gwqkjpwzjj2
[7]	Yan LI, Xuebing YAN, Zhonghua LU, Fang JI. Population distribution of non-alcoholic fatty liver disease before and after renaming and risk factors for liver fibrosis in metabolic dysfunction-associated steatotic liver disease[J]. Journal of Clinical Hepatology, 2024, 40(6): 1136-1141. doi: 10.12449/JCH240611
[8]	Journal of Hepatology｜Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1[J]. Journal of Clinical Hepatology, 2024, 40(3): 508-508. doi: 10.12449/JCH2403.gwqkjpwzjj1
[9]	Journal of the American Medical Association｜Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: A randomized clinical trial[J]. Journal of Clinical Hepatology, 2024, 40(8): 1652-1652. doi: 10.12449/JCH2408.gwqkjpwzjj3
[10]	Journal of Gastroenterology and Hepatology｜Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway[J]. Journal of Clinical Hepatology, 2024, 40(5): 1049-1049. doi: 10.12449/JCH2405.gwqkjpwzjj4
[11]	Journal of Hepatology｜Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1537-1537. doi: 10.12449/JCH2408.gwqkjpwzjj1
[12]	Journal of Hepatology｜Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. Journal of Clinical Hepatology, 2024, 40(2): 257-257. doi: 10.12449/JCH2402.gwqkjpwzjj1
[13]	Nutrition Journal｜Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial[J]. Journal of Clinical Hepatology, 2024, 40(8): 1626-1626. doi: 10.12449/JCH2408.gwqkjpwzjj2
[14]	Hepatology International｜Gut microbiota regulates circadian oscillation in hepatic ischemia-reperfusion injury-induced cognitive impairment by interfering with hippocampal lipid metabolism in mice[J]. Journal of Clinical Hepatology, 2024, 40(1): 109-109. doi: 10.12449/JCH2401.gwqkjpwzjj1
[15]	Journal of Hepatology｜Association of food insecurity with the prevalence and liver-related mortality of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. Journal of Clinical Hepatology, 2024, 40(10): 2126-2126. doi: 10.12449/JCH2410.gwqkjpwzjj3
[16]	Journal of Hepatology｜Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated[J]. Journal of Clinical Hepatology, 2023, 39(2): 407-407. doi: 10.3969/j.issn.1001-5256.2023.02.gwjpwzjj2
[17]	Shihang ZHENG, Jun YANG, Yue TAN, Changqing ZHENG. The mechanism and potential of mammalian target of rapamycin complex 1(mTORC1) in treatment for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(8): 1946-1951. doi: 10.3969/j.issn.1001-5256.2023.08.027
[18]	Journal of Gastroenterology and Hepatology｜A high serum ferritin level increases the risk of death associated with chronic liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(2): 438-438. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj9
[19]	Hepatology｜Myeloid cell-specific IL-6 signal alleviates nonalcoholic fatty liver disease-related fibrosis by promoting the release of microRNA-223-enriched exosome[J]. Journal of Clinical Hepatology, 2022, 38(2): 414-414. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj6
[20]	Wang Fan, Sun Wu, Ma YuLin, Jiang HongJun. Association between microRNA-155/SH2-containing inositol phosphatase-1 and cardiovascular events in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1325-1329. doi: 10.3969/j.issn.1001-5256.2020.06.027